Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer

International Journal of Oncology

Volumn 41, Issue 5, 2012, Pages 1798-1808

  Xue, Yuwen ^a,b   Ren, Hening ^c   Xiao, Wei ^a   Chu, Zuoming ^b   Lee, J Jack ^b   Mao, Li ^c  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

AZ64; Cdc25C; G2 M arrest; Non small cell lung cancer; Phospho Cdc2 (Tyr15)

Indexed keywords

ANTINEOPLASTIC AGENT; AZ 64; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN TARGETING; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMOSOMES, HUMAN; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICROTUBULES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867759994     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1619     Document Type: Article

References (28)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. McErlean A and Ginsberg MS: Epidemiology of lung cancer. Semin Roentgenol 46: 173-177, 2011.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Tun MJ: Cancer statistics. CA Cancer J Clin 56: 106-130, 2006.
4. Hsu HF, Huang KH, Lu KJ, Chiou SJ, Yen JH, Chang CC and Houng JY: Typhonium blumei extract inhibits proliferation of human lung adenocarcinoma A549 cells via induction of cell cycle arrest and apoptosis. J Ethnopharmacol 135: 492-500, 2011.
5. Xu X, Zhang Y, Qu D, Jiang T and Li S: Osthole induces G2/M arrest and apoptosis in lung cancer A549 cells by modulating PI3K/Akt pathway. J Exp Clin Cancer Res 30: 33, 2011.
6. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT and Green S: AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13: 3682-3688, 2007. (Pubitemid 46955132)
7. Harada T, Yatabe Y, Takeshita M, Koga T, Yano T, Wang Y and Giaccone G: Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res 9: 2638-2645, 2011.
8. Yilmaz T, Jiffar T, Garza G, Lin H, Milas Z, Takahashi Y, Hanna E, MacIntyre T, Brown JL, Myers JN, Kupferman ME and Michael E: Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC. Cancer Biol Ther 10 : 644-653, 2010
9. Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, Light JE, Kolla V and Evans AE: Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res 10: 3244-3250, 2009.
10. Koizumi H, Morita M, Mikami S, Shibayama E and Uchikoshi T: Immunohistochemical analysis of TrkA neurotrophin receptor expression in human non-neuronal carcinomas. Pathol Int 2: 93-101, 1998. (Pubitemid 28209067)
11. Thress K, Macintyre T, Wang H, Whitston D, Liu ZY, Hoffmann E, Wang T, Brown JL, Webster K, Omer C, Zage PE, Zeng L and Zweidler-McKay PA: Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther 7: 1818-1827, 2009.
12. Iyer R, Varela CR, Minturn JE, Ho R, Simpson AM, Light JE, Evans AE, Zhao H, Thress K, Brown JL and Brodeur GM: AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts. Cancer Chemother Pharmacol: May 24, 2012 (Epub ahead of print).
13. Castedo M, Perfettini JL, Roumier T and Kroemer G: Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 9: 1287-1293, 2002. (Pubitemid 36097698)
14. Lindqvist A, Rodríguez-Bravo V and Medema RH: The decision to enter mitosis: feedback and redundancy in the mitotic entry network. J Cell Biol 185: 193-202, 2009.
15. Telles E, Gurjar M, Ganti K, Gupta D and Dalal SN: Filamin A stimulates Cdc25C function and promotes entry into mitosis. Cell Cycle 10: 776-782, 2011.
16. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS and Piwnica-Worms H: Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277: 1501-1505, 1997. (Pubitemid 27449237)
17. Toyoshima-Morimoto F, Taniguchi E and Nishida E: Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 4: 341-348, 2002. (Pubitemid 34467604)
18. Seki A, Coppinger JA, Jang CY, Yates JR and Fang G: Bora and the kinase Aurora A cooperatively activate the kinase Plk1 and control mitotic entry. Science 20: 1655-1658, 2008. (Pubitemid 351931258)
19. Choi HJ, Fukui M and Zhu BT: Role of cyclin B1/Cdc2 up-regulation in the development of mitotic prometaphase arrest in human breast cancer cells treated with nocodazole. PLoS One 6: e24312, 2011.
20. Wang ZX, Xue D, Liu ZL, Lu BB, Bian HB, Pan X and Yin YM: Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer. Int J Biochem Cell Biol 44: 200-210, 2012.
21. Lens SM, Voest EE and Medema RH: Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10: 825-841, 2010.
22. Chang DC, Xu N and Luo KQ: Degradation of cyclin B is required for the onset of anaphase in mammalian cells. J Biol Chem 278: 37865-37873, 2003. (Pubitemid 37175315)
23. Jorgensen TJ, Tian H, Joseph IB, Menon K and Frost D: Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth. Cancer Chemother Pharmacol 59: 725-732, 2007. (Pubitemid 46440594)
24. Hsiao YC, Hsieh YS, Kuo WH, Chiou HL, Yang SF, Chiang WL and Chu SC: The tumor-growth inhibitory activity of flavanone and 2′-OH flavanone in vitro and in vivo through induction of cell cycle arrest and suppression of cyclins and CDKs. J Biomed Sci 14: 107-119, 2007.
25. Shyu KG, Huang ST, Kuo HS, Cheng WP and Lin YL: Antitumor activity of a novel bis-aziridinylnaphthoquinone (AZ4) mediating cell cycle arrest and apoptosis in non-small cell lung cancer cell line NCI-H4601. Acta Pharmacol Sin 28: 559-566, 2007.
26. Lee YM, Ting CM, Cheng YK, Fan TP, Wong RN, Lung ML and Mak NK: Mechanisms of 2-methoxyestradiol-induced apoptosis and G2/M cell-cycle arrest of nasopharyngeal carcinoma cells. Cancer Lett 268: 295-307, 2008.
27. Zhang HY, Gu YY, Li ZG, Jia YH, Yuan L, Li SY, An GS, Ni JH and Jia HT: Exposure of human lung cancer cells to 8-chloro-adenosine induces G2/M arrest and mitotic catastrophe. Neoplasia 6: 802-812, 2004. (Pubitemid 40041499)
28. Chen YL, Lin SZ, Chang JY, Cheng YL, Tsai NM and Chen SP: In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells. Biochem Pharmacol 72: 308-319, 2006.